Reference entry · Synthetic p53-derived peptide
PNC-27
Also known as: p53-derived peptide · MDM-2 binding peptide
- Class
- Synthetic p53-derived peptide
- Size
- 27 amino acids
- Primary targets (literature)
- MDM-2 interaction literature; membrane permeabilization in cancer cell models
- Regulatory context
- Investigational only — not FDA-approved. Oncology preclinical findings do not establish human treatment utility.
Overview
PNC-27 is a synthetic peptide derived from p53 sequence elements, studied in preclinical oncology models for selective cytotoxicity against certain transformed cell lines. Evidence is predominantly in vitro and early animal work.
Mechanism in research literature
Published models propose MDM-2 binding and membrane disruption in p53-deficient or MDM-2–overexpressing cell lines — highly cell-line and protocol dependent.
Common research focus areas
- In vitro cytotoxicity in defined cell lines
- MDM-2 interaction and p53-pathway research
- Oncology model limitations and replication
- 27-mer sequence confirmation and purity
Full literature roundup
Read the cited research summary
A synthetic p53-derived peptide studied in preclinical oncology models. What selective cytotoxicity literature reports — and where human evidence ends.
PNC-27 research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.